Short answer
Design Therapeutics, Inc. (DSGN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$20M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$20M
- −19.4% YoY · −0.6% QoQ
- EPS (diluted)
- −$0.32
- −6.7% YoY · +0.0% QoQ
Source: XBRL data from the Design Therapeutics, Inc. (DSGN) Q3 2026 10-Q on SEC EDGAR. USD.
Design Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $0, unchanged YoY, no approved products or product sales
- Operating expenses $22.2M vs $19.3M YoY, research and development $16.9M vs $14.6M
- Best program: DM1 R&D $3.3M, up from $0; worst: FECD $1.6M vs $(1.1)M
- Cash, equivalents and investments $208.6M, down $11.2M from December 31, 2025
- Operating cash use $47.3M; ATM financing $37.1M, runway more than 12 months
Risk Factors
- Newly added trade-policy risk: 2025 tariffs and potential sanctions threaten foreign API supplies, increasing development costs and disrupting clinical timelines
- Most materially updated manufacturing risk: BIOSECURE Act restrictions could limit use of Chinese biotechnology suppliers after the mid-December 2026 designation list
- Regulatory risk: Loper Bright decision increases challenges to FDA rules and uncertainty around agency interpretations
- Near-term clinical risk: omaveloxolone availability may reduce FA trial enrollment for DT-216P2
- Financial risk: $208.6 million in cash, equivalents and investments funds operations over 12 months but not regulatory approval or commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Design Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.